Skip to main content
S&P 5007,591.70-0.58%DOW52,064.10-0.60%NASDAQ26,081.72-0.65%BTC$76,984.00-0.94%ETH$2,457.16+0.01%GOLD$4,369.60-0.86%OIL$99.56-2.85%
Smart Investors Daily
Jazz Pharmaceuticals plc logo

NASDAQ · JAZZ

Jazz Pharmaceuticals plc

Healthcare · Biotechnology

$240.48

Down-$0.83 (-0.34%)

Updated Sep 11, 2026, 12:02 PM

SID Score

6.2/10

Composite research score

Smart Money

58/100

Neutral

Market cap
10.02B
P/E ratio
-27.16
Dividend yield
0.00%
52-week range
$156.95 – $266.38
Volume
1.03M
Avg. volume
1.03M

Price performance

JAZZ price history

1M range · 20 trading sessions · Daily adjusted prices

JAZZ closed at $240.48 after 20 trading sessions, down 2.18% for the selected period.

Last close
$240.48
Period change
-2.18%
Period low
$240.07
Period high
$260.23
Daily close
View OHLC price history
JAZZ OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 10, 2026$240.94$244.46$239.285$240.481.03M
Sep 9, 2026$238.38$241.44$236.00$241.31424.47K
Sep 8, 2026$240.00$244.71$239.11$240.07467.91K
Sep 4, 2026$246.00$249.00$244.745$246.81321.87K
Sep 3, 2026$246.92$248.91$241.865$247.565507.62K
Sep 2, 2026$244.00$248.07$241.02$245.571.16M
Sep 1, 2026$250.13$252.495$243.02$243.711.07M
Aug 31, 2026$241.39$252.715$241.39$250.681.22M
Aug 28, 2026$249.48$250.64$244.4901$244.541.19M
Aug 27, 2026$250.00$252.85$246.99$251.104.74M
Aug 26, 2026$257.40$259.83$248.52$249.292.37M
Aug 25, 2026$256.36$266.375$254.585$260.231.56M
Aug 24, 2026$253.66$254.70$250.44$254.47420.09K
Aug 21, 2026$248.75$255.85$248.55$254.28516.75K
Aug 20, 2026$249.60$254.93$245.76$248.70439.92K
Aug 19, 2026$255.65$256.915$251.26$252.16549.52K
Aug 18, 2026$248.73$256.41$248.73$253.07459.26K
Aug 17, 2026$244.00$248.52$243.16$248.36504.87K
Aug 14, 2026$243.59$245.35$240.631$244.96542.04K
Aug 13, 2026$251.38$251.38$243.74$245.85468.03K

Latest JAZZ news

The latest Smart Investors Daily articles mentioning JAZZ.

Stock researchCompany · Overview

JAZZ research

Overview

Company profile and research snapshot.

Company profile

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$190.43
Implied upside
—
Analysts
—
JAZZ recent ratings
DateFirmRatingTarget
Aug 26, 2026Morgan StanleyOverweight—
Aug 26, 2026Deutsche BankBuy—
Aug 26, 2026Truist SecuritiesBuy—
Aug 26, 2026NeedhamBuy—
Aug 11, 2026Morgan StanleyOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 4, 2026

Jazz (JAZZ) Says Ziihera Beat Trastuzumab on Overall Survival. Can it Replace the First-Line HER2 Backbone?

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) reported that Ziihera plus chemotherapy produced a statistically significant and clinically meaningful overall-survival benefit over trastuzumab plus chemotherapy in the Phase 3 HERIZON-GEA-01 trial. Jazz Pharmaceuticals plc (NASDAQ:JAZZ) said the overall-survival hazard ratio improved from the first interim analysis, when the result favored Ziihera but was not statistically significant. The global, […]

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By